Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke

Guangzhu Zhang,Ying Li,James L. Reuss,Nan Liu,Cuiying Wu,Jingpo Li,Shuangshuang Xu,Feng Wang,Thomas G. Hazel,Miles Cunningham,Hongtian Zhang,Yiwu Dai,Peng Hong,Ping Zhang,Jianghong He,Huiru Feng,Xiangdong Lu,John L. Ulmer,Karl K. Johe,Ruxiang Xu
DOI: https://doi.org/10.1002/sctm.18-0220
2019-06-26
Stem Cells Translational Medicine
Abstract:Abstract NSI-566 is a stable, primary adherent neural stem cell line derived from a single human fetal spinal cord and expanded epigenetically with no genetic modification. This cell line is being tested in clinical trials in the U.S. for treatment of amyotrophic lateral sclerosis and spinal cord injury. In a single-site, phase I study, we evaluated the feasibility and safety of NSI-566 transplantation for the treatment of hemiparesis due to chronic motor stroke and determined the maximum tolerated dose for future trials. Three cohorts (n = 3 per cohort) were transplanted with one-time intracerebral injections of 1.2 × 107, 2.4 × 107, or 7.2 × 107 cells. Immunosuppression therapy with tacrolimus was maintained for 28 days. All subjects had sustained chronic motor strokes, verified by magnetic resonance imaging (MRI), initiated between 5 and 24 months prior to surgery with modified Rankin Scores [MRSs] of 2, 3, or 4 and Fugl-Meyer Motor Scores of 55 or less. At the 12-month visit, the mean Fugl-Meyer Motor Score (FMMS, total score of 100) for the nine participants showed 16 points of improvement (p = .0078), the mean MRS showed 0.8 points of improvement (p = .031), and the mean National Institutes of Health Stroke Scale showed 3.1 points of improvement (p = .020). For six participants who were followed up for 24 months, these mean changes remained stable. The treatment was well tolerated at all doses. Longitudinal MRI studies showed evidence indicating cavity-filling by new neural tissue formation in all nine patients. Although this was a small, one-arm study of feasibility, the results are encouraging to warrant further studies. Stem Cells Translational Medicine 2019;8:999–1007
cell & tissue engineering
What problem does this paper attempt to address?
This paper attempts to solve the problem of paralysis caused by ischemic stroke. Specifically, the researchers evaluated the safety and feasibility of NSI - 566 neural stem cell transplantation in the treatment of hemiplegia after chronic motor stroke, and determined the maximum tolerated dose for future trials. NSI - 566 is a primary human neural stem cell line isolated from a single human fetal spinal cord tissue, amplified by epigenetic means and not genetically modified. The study was divided into three cohorts, with 3 patients in each cohort, receiving a single intracerebral injection of 1.2×10^7, 2.4×10^7 and 7.2×10^7 cells respectively. The main objectives of the study were to evaluate the safety and maximum tolerated dose at different doses, and at the same time observe the clinical improvement of patients. The results of the study showed that at 12 months, the average Fugl - Meyer Motor Score (FMMS) of the 9 participants increased by 16 points (p = 0.0078), the average modified Rankin Scale (MRS) score increased by 0.8 points (p = 0.031), and the average National Institutes of Health Stroke Scale (NIHSS) score increased by 3.1 points (p = 0.020). These improvements remained stable at 24 months. Longitudinal MRI studies showed that the formation of new neural tissue in all 9 patients filled the lacunae. The treatment was well - tolerated at all doses, and no more safety problems occurred at the highest tested dose of 7.2×10^7 cells. In conclusion, this study preliminarily demonstrated the safety and potential efficacy of NSI - 566 neural stem cell transplantation in the treatment of hemiplegia after chronic motor stroke, providing a basis for further large - scale randomized controlled trials.